|
gptkbp:instanceOf
|
gptkb:drug
gptkb:insulin
cytokine
|
|
gptkbp:administeredBy
|
injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
1986
|
|
gptkbp:ATCCode
|
gptkb:L03AB05
|
|
gptkbp:CASNumber
|
121181-53-1
|
|
gptkbp:contraindication
|
autoimmune hepatitis
severe psychiatric disorders
|
|
gptkbp:developedBy
|
gptkb:Schering-Plough
|
|
gptkbp:halfLife
|
2-3 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
interferon alfa-2b
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
Intron A
|
|
gptkbp:mechanismOfAction
|
inhibits viral replication
stimulates immune response
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
recombinant DNA technology
|
|
gptkbp:routeOfAdministration
|
intramuscular
subcutaneous
|
|
gptkbp:sideEffect
|
gptkb:depression
gptkb:anemia
fatigue
neutropenia
flu-like symptoms
|
|
gptkbp:UNII
|
gptkb:P18312
|
|
gptkbp:usedFor
|
gptkb:hairy_cell_leukemia
gptkb:hepatitis_C
gptkb:hepatitis_B
gptkb:AIDS-related_Kaposi's_sarcoma
follicular lymphoma
malignant melanoma
condyloma acuminatum
|
|
gptkbp:usedInCOVID19
|
investigational
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:INTRON_A
|
|
gptkbp:bfsLayer
|
6
|